Unity Biotechnology Inc. (NASDAQ:UBX) does about 1.27M shares in volume on a normal day but saw 2049317 shares change hands in Friday trading. The company now has a market cap of 157.20M USD and an enterprise value of about $74.39M. Its current market price is $2.98, marking a decrease of -1.32% compared to the previous close of $3.02. The 52 week high reached by this stock is $15.44 whilst the lowest price level in 52 weeks is $2.87. The script in recent trading has seen the stock touch a high of $3.08 and a low of $2.93.

Unity Biotechnology Inc. (UBX) has a 20-day trading average at $8.72 and the current price is -80.70% off the 52-week high compared with 3.83% distance from its 52-week low. The 50-day simple moving average of the closing price is $8.64 and its 200-day simple moving average is $7.26. If we look at the stock’s price movements over the week, volatility stands at 16.36%, which decreases to 11.45% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 23.60 to suggest the stock is oversold.

6 analysts observing the Unity Biotechnology Inc. (UBX) stock have set the 12-month price targets for the company’s shares at between $4.00 and $12.00. The median price target is 33.78% away from the current levels at $4.50.

FactSet Research has provided data showing that 6 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 5 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 18, 2020 when Morgan Stanley downgraded the stock to “Equal-Weight” and issued a price target of $5. Mizuho also downgraded the stock to “Neutral” from Buy on August 18, 2020 at a price target of $33-$4. Citigroup downgraded its price target at $31-$5.

The current price level is -66.82%, -65.98%, and -59.09% away from its SMA20, SMA50, and SMA200 respectively, with the UBX price moving above the 50-day SMA on August 21. Unity Biotechnology Inc. (UBX) stock is down -76.03% over the week and -64.82% over the past month. Its price is -58.67% year-to-date and -50.66% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.38 above consensus estimates by $0.13. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$0.49 and -$2.31 for whole year. UBX’s earnings per share are forecast to shrink by -22.90% this year and 26.00% over next year.

Its 12-month price target is $4.50. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $4.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $12.00.

Outstanding shares total 49.66M with insiders holding 19.40% of the shares and institutional holders owning 70.98% of the company’s common stock. The company has a return on equity of -76.30%. Price to book ratio is 1.32.

According to a U.S. Securities and Exchange Commission filing, Scottish Mortgage Investment Trus has reduced its position in Unity Biotechnology Inc. (UBX) to 3,209,964 shares, mirroring a recent drop by -0.12%. Scottish Mortgage Investment Trus dumped 3939.0 shares of Unity Biotechnology Inc. common stock bringing its total worth to about $30.27 million at the end of recent close, SEC documents show. Scottish Mortgage Investment Trus isn’t the only investment manager who changed stakes and is followed by Fidelity Growth Company Fund, which sold off 7099.0 shares to end up with 2,682,599 shares worth $25.3 million. American Funds Small Cap World Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 3.73% position in Unity Biotechnology Inc. thanks to 1.83 million shares amounting to $17.3 million.